NASDAQ
45.75USD
+0.85 (+1.89%)
We have scored 35 news catalysts on Ionis Pharmaceuticals, Inc. (IONS) over the past 12 months. The biggest single-day move next to one of them came Jul 9, 2026, when IONS closed −23.9%: “AstraZeneca shares plunge as Wainua fails late-stage heart disease trial”. Coverage across the window leans positive (average ticker sentiment +0.16). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
7.6B
P/E
—
EPS
—
Beta
0.42
52W range
44.2-86.74
Day range
44.44–46.13
Open
44.96
Prev close
44.90
Volume
4.2M
Avg volume
3M
Dividend
0.00
IPO
1991-05-17
Analysts publish price targets on IONS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
19 analyst price targets from $54 to $130
as of 2026-09-14
The market is 37% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Ionis Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IONS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
At $45.75, the stock sits at the 5th percentile of published models, meaning the market has largely dismissed the bullish consensus and is pricing in the failure of key pipeline assets following recent clinical setbacks.
What the disagreement turns on
Does the Pelacarsen HORIZON trial succeed in reducing cardiovascular events, and can Tryngolza's prescription volume confirm that Ionis can capture multi-billion-dollar markets—neither of which can be settled by the currently wired data.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $54.21 on 2026-09-14 — the quote has since moved -16%, so read this as a record of what was priced in then, not now.
